Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
If this data is so unimportant as to not warrant an RNS then why release an RNS for any of it at all.
Nov 2021 RNS Nuformix plc notes clinical data on NXP002
Shareholders have every right to question why this BoD never seems to keep its word.
B009, when did they say they would issue an RNS when they got durability data?
Soup,
So you are saying the BOD put RNS with promises that they won't fulfill?
You are showing so much confidents for a bod who fails to fulfil or update their commitments which they have stated publicly!
If you are right then pretty obvious the price is going to drop a lot! I say we will see 50s in the coming months. Will be lucky if it find floor at 50!. I guess people who entered last years can kiss good buy to their investments!
At times like this, I always find it useful, helpful & reassuring when everyone comes on to the bb day after day and says “we really need news”. I normally find that helps, cos more often than not, it’s just that the BoD have loads to tell us, and they’ve just forgotten to announce it lol.
Furthermore, by continually stating that “we need news” over and over again, the price, most probably will start to go up.
GL all
B009,
Its clear DG is in lieu of a BDD as the company hasn't mentioned it since the circular note at the end of January.
Do you really want the company to say they aren't bothering with a CEO? They've stopped looking? What do you think would happen to the sp if they announced that?
Data received from the CRO is not price sensitive as it doesn't affect revenue so doesn't have to be made public.
Soup, for someone who has posted loads and loads data here, I'm bit puzzled with your response! do you even read the RNS?
"1-Dan Gooding was brought in as business development consultant in lieu of director level appointment" - Where does it say that? you just assumed didn't you?
"2-CEO was progressing, but doesn't mean they have to appoint someone, there may be circumstances that mean one is not required." - Agree 100% if thats the case then BOD should update the shareholders specially when they mentioned the CEO hunt in few RNS, Don't you think its courtesy to let everyone know?
"3-What makes you think positive data has not been received?" - If you seen the that please share it with us, I'm not sure about others but I didn't see any RNS.
I'm with FX, it's price sensitive has to be RNS'd surely, if not why don't they just never release RNS's
What good reason would there be to tell shareholders that data is expected in early 2022, receive good data and then keep it quiet?
Given the horrendous price we find ourselves at, how could that possibly be in the best interest of shareholders?
1-Dan Gooding was brought in as business development consultant in lieu of director level appointment.
2-CEO was progressing, but doesn't mean they have to appoint someone, there may be circumstances that mean one is not required.
3-What makes you think positive data has not been received?
B009, spot on mate. They need to do simple things first before dreaming big.
People talking about licensing here is like some people thoughts 'what will I do with money if I win the lottery'
Before winning the lottery first needs to play the lottery, then need to select the number and then the selected number need to match the winning numbers.
Likewise there are other more important things hat NFX need to address before there is any conversation regarding licensing!.
How about starting with delivering what was stated in the RNSs
1) BDD, God knows...
2) CEO, was progressing well in April.
3) positive data which was expected early 22!
I think Licensing talks are bit too rich at this stage for a BOD who cant deliver or give an update on 3 simple things!
"Just to be clear about this, licensing discussions with pharmaceutical companies take a long time and when you get to the beginnings of a deal usually takes six to twelve months for that to happen"
So we may be approaching that six month point now on NXP004 - who knows!
DG has presumably already had talks in Japan taking up where they left off two years ago before the pandemic.
So lots tom play for in two billion pound amrkets.
Apologies for corrected posts - fat finger syndrome with phone
ATB